Irish fintech Fineos raises €44m through institutional placing

Irish insurance software company Fineos has raised $70 million Australian dollars (€43.8 million) through an institutional placement in Sydney.

The company, which recently surpassed €100 million in annual revenues for the first time, issued about 16.3 million new fully-paid chess depositary interests (CDI) over ordinary shares, at an offer price of $4.30 per new CDI.

The placement price represents a 5.1 per cent discount to the company’s closing price of $4.53 per CDI on Thursday.

Founded in Dublin by Michael Kelly in 1993 and now employing more than 1,000 people, Fineos raised about €130 million when it became the first Irish-headquartered company to float on the stock exchange in Australia in August 2019.

Irish-based subsidiary of Adobe to pay $4.8bn in dividends

---

Boscasports seals deal with Tote Ireland for digital displays

---

YouTube music services hit 50m subscribers in race to catch Spotify

---

Chinese teens vent at new gaming limits as investors weigh impact

---

The company is a provider of software solutions for global life, accident and health insurance companies. It counts seven of the top 10 group life and health carriers in the US, and six of the top 10 in Australia, among its customers.

The fintech, which is still headquartered in Dublin, recorded revenues of €108.3 million for its full-year, up 23.3 per cent on the €87.7 million reported a year earlier. Annual recurring revenues – an important metric for software-as-a-service (Saas) companies – totalled €45.7 million. Earnings before interest, tax, depreciation and amortisation (ebitda) was down 49.7 per cent to €7.9 million from €15.7 million.

The company currently has a market capitalisation of $1.38 billion (€860 million).

Fineos said the new funds will be used to provide working capital and balance sheet support for planned R&D investments and growth opportunities.

It is in acquisition mode, acquiring US company Spraoi in a transaction worth up to $10.6 million (€8.9 million) in May. It also bought fellow US firm Limelight Health in a €63.6 million deal last year.